At least nine biotechs and pharmas reported earnings last week. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) hit a 52-week high of $331.64 after beating the Street's EPS and revenue estimates. For 2014, the biotech expects U.S. sales for ophthalmic drug Eylea aflibercept to be $1.7-$1.8 billion, in line with the consensus estimate of $1.76 billion. Regeneron added $2.4 billion to its market cap last week. Shire plc (LSE:SHP; NASDAQ:SHPG) gained $1.6 billion in market value after beating the Street's estimates. In addition to earnings, the company announced that Graham Hetherington is stepping down as CFO and a director, effective March 1 (see B10). Ligand Pharmaceuticals Inc. (NASDAQ:LGND) gained 28% last week after beating consensus EPS and revenues estimates. 4Q13 royalty revenues were up 48% to $7.1 million primarily due to thrombocytopenia drug Promacta eltrombopag and multiple myeloma drug Kyprolis carfilzomib. Acorda Therapeutics Inc. (NASDAQ:ACOR) gained 10% on the week after beating the Street's revenue estimate. The company markets Ampyra dalfampridine to improve walking ability in multiple sclerosis patients. (A) Fiscal 3Q earnings; Mcap in $M


4Q13 EPS est

4Q13 EPS actual


Growth from 4Q12

2/14 cls

Wk chg

% chg

Mcap chg

2/14 Mcap

Acorda Therapeutics Inc. (NASDAQ:ACOR)



Missed by $0.03







4Q13 revenues were $95.6M, up 14% from $81.5M in 4Q12 and above the Street's estimate of $90.7M. Sales of Ampyra dalfampridine, which is approved to improve walking ability in multiple sclerosis patients, increased 16% to $84.6M. Acorda expects Ampyra net revenues of $328-$335M in 2014.